Sugi Predict

Sugi Predict / Compounds / SCHEMBL111872

SCHEMBL111872

SCHEMBL111872

O=C(O)c1c(Cl)cncc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 6/20 0.46
▸ DPP4 P27487 1/20 0.44
▸ HDAC3 O15379 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HDAC9 Q9UKV0 1/20 0.39
▸ HDAC5 Q9UQL6 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ITGB1 P05556 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5760445 0.97 HCAR2 (0.45) HCAR2DPP4HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL5204506 0.97 HCAR2 (0.45) HCAR2DPP4HDAC3HDAC4HDAC1
Formaldehyde SCHEMBL28038712 0.95 HCAR2 (0.43) HCAR2DPP4HDAC3HDAC4HDAC1
Nitrous Acid SCHEMBL28928125 0.91 HCAR2 (0.41) HCAR2DPP4HDAC3HDAC4HDAC1
SCHEMBL16135687 0.84 HCAR2 (0.39) HCAR2DPP4HDAC3HDAC4HDAC1
SCHEMBL3667385 0.84 ALDH1A1 (0.42) HCAR2DPP4HDAC3HDAC4HDAC1
SCHEMBL21825962 0.84 HDAC3 (0.41) HCAR2DPP4HDAC3HDAC4HDAC1
SCHEMBL31446649 0.84 HCAR2 (0.39) HCAR2DPP4HDAC3HDAC4HDAC1
SCHEMBL6125229 0.84 ALDH1A1 (0.46) HCAR2DPP4HDAC3HDAC4HDAC1
SCHEMBL844329 0.81 HCAR2 (0.37) HCAR2DPP4HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136886-A PDE4 inhibitor with pyranonaphthyridone skeleton and preparation method and application thereof 中山大学 2025-06-13 — — CN claimed
CN-122028913-A Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions 阿达尔克斯制药有限公司 2026-05-12 — — CN disclosed
US-20260000775-A1 a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2026-01-01 — — US disclosed
US-20250333406-A1 SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYSOWAY THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
CN-120136886-A PDE4 inhibitor with pyranonaphthyridone skeleton and preparation method and application thereof 中山大学 2025-06-13 — — CN disclosed
WO-2025080995-A1 PHARMACEUTICAL AGENT-INTEGRIN LIGAND CONJUGATES FOR MUSCLE DELIVERY ADARX PHARMACEUTICALS, INC. (US) 2025-04-17 — — WO disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
WO-2025038971-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO disclosed
CN-119486739-A α4β1/7Integrin ligand conjugated compounds and uses thereof 阿达尔克斯制药有限公司 2025-02-18 — — CN disclosed
EP-4504196-A1 ALPHA4BETA1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-02-12 — — EP disclosed
EP-0550112-A1 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them STERLING WINTHROP INC. (US) 1993-07-07 — — EP disclosed
EP-0550111-A1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them STERLING WINTHROP INC. (US) 1993-07-07 — — EP disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 — — US disclosed
US-4812565-A ANTIHISTAMINE INTERMEDIATES A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-14 — — US disclosed
US-4810795-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1989-03-07 — — US disclosed
US-4727152-A Intermediates useful in the preparation of fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1988-02-23 — — US disclosed
US-4705853-A ANTIHISTAMINES A. H. ROBINS COMPANY, INC. (US) 1987-11-10 — — US disclosed
US-4642343-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1987-02-10 — — US disclosed
US-4604388-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine A. H. ROBINS COMPANY, INCORPORATED (US) 1986-08-05 — — US disclosed
US-4592866-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1986-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000775-A1 a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ITGB1, ITGB4, ITGA4 HCAR2 3005/4885DPP4 949/4885HDAC3 2155/4885
US-20250333406-A1 SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF STOML2, ATP2A3, ATP2A1 HCAR2 3526/4885DPP4 552/4885HDAC3 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.